Scientific publications

Adjuvants for allergy immunotherapeutics

Gamazo C (1), D Amelio C (2), Gastaminza G (3), Ferrer M (4), Irache JM (5). (1a) Dept. Microbiology, Instituto de Investigación Sanitaria de Navarra (Idisna), University of Navarra - C/Irunlarrea, 1; 31080 - Pamplona, Spain
(2b) Department of Allergology and Clinical Immunology, Clínica Universidad de Navarra - address: Av. Pio XII 36, 31008-Pamplona-Spain.
(3c) Department of Allergology and Clinical Immunology, Clínica Universidad de Navarra - address: Av. Pio XII 36, 31008-Pamplona-Spain.
(4d) Department of Allergology and Clinical Immunology, Clínica Universidad de Navarra - address: Av. Pio XII 36, 31008-Pamplona-Spain.
(5e) University of Navarra , Dept. Pharmacy and Pharmaceutical Technology; C/Irunlarrea, 1; 31080 - Pamplona, Spain.

Magazine: Human Vaccines & Immunotherapeutics

Date: Aug 21, 2017

Allergology and Immunology Department

ABSTRACT

Allergic diseases are reaching epidemic proportions in developed countries. In particular, food allergy is increasing in prevalence and severity, thus becoming an important socioeconomic burden. Numerous cell types and cell populations, which form an intricate and balanced network, are involved in an immune response.

This balance is occasionally disturbed, leading to the onset of different diseases, such as allergic diseases. Antihistamines and corticosteroids provide some degree of relief from the symptoms of allergic conditions. However, the only treatment that can revert the disease is immunotherapy. Nevertheless, specific immunotherapy has at least two major drawbacks: it is time-consuming, and it can produce local and even systemic allergic side effects. Immunotherapy's potential goes beyond our current knowledge of the immune response; nevertheless, we can still design strategies to reach a safer immune modulation for treating allergies.

This review deals with the use of adjuvants to reduce the undesirable side effects associated with specific allergen immunotherapy. For example, nanoparticles used as immunoadjuvants are offering promising results in preclinical assays.

CITATION  Hum Vaccin Immunother. 2017 Aug 21:0. doi: 10.1080/21645515.2017.1348447

you mayBE INTERESTED

WHAT TECHNOLOGY
DO WE USE?

The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OUR
PROFESSIONALS

The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra

WHY CHOOSE
THE CLINICA?

Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra